Multi-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen With Clinical, Histopathologic, Immunohistochemical, Photographic, and Ultrasound Evaluation

April 2018 | Volume 17 | Issue 4 | Original Article | 426 | Copyright © April 2018


Amy Taub MD,a Vivian Bucay MD,b Gregory Keller MD,c Jay Williams PhD,c and Darius Mehregan MDd

aAdvanced Dermatology/Skinfo, Lincolnshire, IL; Northwestern University Medical School, Department of Dermatology, Chicago, IL bBucay Center for Dermatology and Aesthetics, San Antonio, TX cGregory Keller Plastic Surgery, Santa Barbara, CA dWayne State University, Monroe, MI

Figure 8were 0.023 for evenness and 0.008 for oiliness. Participants #22, #23, and #24 (all FFG) were excluded from the QuantifiCare analysis of skin’s oiliness, evenness, and pore size due to the missing data on week 12 (no measurements). Pigmentation was also significantly reduced, as measured by the SkinLab Combo Suite. Site 3 subjects (11 full formula and 4 placebo) showed the average pigmentation index in the FFG was decreased from 42.09 to 40.35 after 6 weeks treatment (Figure 9C). The PG did not demonstrate improvement (pigmentation indexes were 41.45 and 41.52 at baseline and 6 weeks, respectively). This finding was statistically significant Table 5Table 6